<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordsOutput xmlns:ns2="local"><serviceExecutionTime>563</serviceExecutionTime><Drug id="100007"><DrugName>GSK-3008348</DrugName><DrugSynonyms><Name><Value>GSK-3008348</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>alpha-V/beta-6 integrin antagonist (idiopathic pulmonary fibrosis), GSK</Value></Name></DrugSynonyms><CompanyOriginator id="28355">GlaxoSmithKline plc</CompanyOriginator><CompaniesSecondary><Company id="28355">GlaxoSmithKline plc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="28355" type="Company"><TargetEntity id="4295895781" type="organizationId">GlaxoSmithKline PLC</TargetEntity></SourceEntity><SourceEntity id="3771" type="ciIndication"><TargetEntity id="J84.112" type="ICD10"></TargetEntity><TargetEntity id="10021240" type="MEDDRA"></TargetEntity><TargetEntity id="D054990" type="MeSH"></TargetEntity><TargetEntity id="2032" type="ORPHANET"></TargetEntity><TargetEntity id="-1110748304" type="omicsDisease"></TargetEntity><TargetEntity id="289" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity></SourceEntity><SourceEntity id="PTGT-01150" type="ciTarget"><TargetEntity id="57571" type="siTarget">Integrin alphavbeta6 receptor</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C1">Phase 1 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="3771">Idiopathic pulmonary fibrosis</Indication></IndicationsSecondary><ActionsPrimary><Action id="2961">Integrin alpha-V/beta-6 antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="2953">Anti-inflammatory</Action></ActionsSecondary><Technologies><Technology id="616">Inhalant formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2019-02-09T18:32:40.000Z</LastModificationDate><ChangeDateLast>2019-02-11T00:00:00.000Z</ChangeDateLast><AddedDate>2015-11-26T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="28355" linkType="Company"&gt;GlaxoSmithKline&lt;/ulink&gt;, in collaboration with the &lt;ulink linkID="20640" linkType="Company"&gt;University of  Nottingham&lt;/ulink&gt;, was developing  GSK-3008348, a selective naphthyridine lead from a program of alpha-V/beta-6 integrin antagonists,   for the potential nebulizer-inhaled treatment of idiopathic pulmonary fibrosis (IPF) [&lt;ulink linkID="1715562" linkType="Reference"&gt;1715562&lt;/ulink&gt;]. In December 2015, a phase I trial began [&lt;ulink linkID="1719027" linkType="Reference"&gt;1719027&lt;/ulink&gt;]; in June 2017, another phase I trial was initiated in IPF patients [&lt;ulink linkID="1906931" linkType="Reference"&gt;1906931&lt;/ulink&gt;]. In July 2018, proof-of-concept data were expected in second half of 2020 [&lt;ulink linkID="2059415" linkType="Reference"&gt;2059415&lt;/ulink&gt;]. In October 2018, the drug was still listed as being in phase I development for IPF [&lt;ulink linkID="2093964" linkType="Reference"&gt;2093964&lt;/ulink&gt;]. In January 2017, a phase IIa trial was planned to start in 2018 [&lt;ulink linkID="1892092" linkType="Reference"&gt;1892092&lt;/ulink&gt;]. However, in February 2019, the drug had discontinued development [&lt;ulink linkID="2117968" linkType="Reference"&gt;2117968&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In January 2017, a phase IIa trial was planned to start in 2018 [&lt;ulink linkID="1892092" linkType="Reference"&gt;1892092&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2017, a randomized,  parallel assignment, interventional,  single dose phase I trial (&lt;ulink linkID="289891" linkType="Protocol"&gt;NCT03069989&lt;/ulink&gt;; 204715)  was to be initiated in patients (expected n = 17) with IPF to assess the safety, tolerability, pharmacokinetics and target engagement of   GSK-3008348 using PRT imaging. At that time, the trial was expected to start in April 2017 and complete in February 2018. In June 2017, the trial was initiated in the UK. At that time, the study was expected to complete in September 2018.  In May 2018, recruitment for the trial was ongoing; at that time, the trial was expected to complete in  May 2019 [&lt;ulink linkID="1906931" linkType="Reference"&gt;1906931&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2015, a randomized, interventional,  crossover assignment, double blind, phase I  trial (&lt;ulink linkID="246595" linkType="Protocol"&gt;NCT02612051&lt;/ulink&gt;; 200262) was planned to be initiated in the UK in patients (expected n = 70) with idiopathic pulmonary fibrosis  to assess the safety and efficacy of GSK-3008348. At that time,  the trial was expected to complete in November 2016 [&lt;ulink linkID="1719027" linkType="Reference"&gt;1719027&lt;/ulink&gt;]. In December 2015, the trial was initiated; it was completed in June 2016 following enrollment of 40 patients  [&lt;ulink linkID="1719027" linkType="Reference"&gt;1719027&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In September 2018, in vitro data were presented at XXV EFMC-ISMC Symposium in Ljubljana, Slovenia. GSK-3008348 demonstrated excellent affinity for the target alpha-v-beta 6 due to three key polar binding interactions, enabling the compound an effective RGD mimetic  [&lt;ulink linkID="2068998" linkType="Reference"&gt;2068998&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2017, data were presented at the 19th RSC-SCI Medicinal Chemistry Symposium in Cambridge, UK. In a 14-day bleomycin mouse model of IPF GSK-3008348 showed activity at a dose of 1 mg/kg, and was able to inhibit collagen production when dosed prophylactically. In slices of human IPF lungs it inhibited TGFbeta and pSMAD2 [&lt;ulink linkID="1967164" linkType="Reference"&gt;1967164&lt;/ulink&gt;], [&lt;ulink linkID="1964059" linkType="Reference"&gt;1964059&lt;/ulink&gt;]&lt;/para&gt;&lt;para&gt;In April 2017, preclinical data were presented at the 253rd ACS National Meeting and Exhibition in San Francisco, CA. In human bronchial epithelial cells, GSK-3008348 induced rapid intrinsic ligation, followed by liposomal degradation with pEC50 value of 9.76 nM. GSK-3008348 (0.0005 to 1 mg/kg) exhibited a pIC50 value of 9.13 against alpha-v-beta-6 in vivo in a bleomycin (3 mg/kg) treated SPECT LCT mouse model [&lt;ulink linkID="1914658" linkType="Reference"&gt;1914658&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2015, preclinical data were presented at the First RSC-SCI Fibrosis Disease Symposium, Slough, UK. The compound, GSK-3008348 had a PIC50 of 8.4 at the alpha-V/beta-6 integrin receptor and PIC50 of 6, 6.9 and 7.7 at beta-3, beta-5 and beta-8 receptors, respectively. Improvement in potency and selectivity was achieved by exploring heterocyclic substituents such as the dimethylpyrazole [&lt;ulink linkID="1715562" linkType="Reference"&gt;1715562&lt;/ulink&gt;].  &lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3771">Idiopathic pulmonary fibrosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-03-06T00:00:00.000Z</StatusDate><Source id="2117968" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3771">Idiopathic pulmonary fibrosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-11-10T00:00:00.000Z</StatusDate><Source id="1715562" type="CONFERENCE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3771">Idiopathic pulmonary fibrosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1715562" type="CONFERENCE"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-01150"><Name>Integrin alpha-V/beta-6</Name><SwissprotNumbers><Swissprot>P06756</Swissprot><Swissprot>P18563</Swissprot><Swissprot>P18564</Swissprot><Swissprot>P26008</Swissprot><Swissprot>P43406</Swissprot><Swissprot>P80746</Swissprot><Swissprot>Q9Z0T9</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=2117968" linkType="reference" linkID="2117968"&gt;2117968&lt;/ulink&gt;]
							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="20640">University of Nottingham</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="28355">GlaxoSmithKline plc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="7">Drug - Development Services</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="159469" title="University of Nottingham to conduct research on GlaxoSmithKline's GSK-3008348 against Idiopathic pulmonary fibrosis          "></Deal></Deals><hasSWOTs>N</hasSWOTs></Drug><Drug id="100008"><DrugName>macrocyclic ligands (idiopathic pulmonary fibrosis), Fidelta</DrugName><DrugSynonyms><Name><Value>macrocyclic ligands (idiopathic pulmonary fibrosis), Fidelta</Value></Name></DrugSynonyms><CompanyOriginator id="1009875">Fidelta Ltd</CompanyOriginator><CompaniesSecondary><Company id="1009875">Fidelta Ltd</Company></CompaniesSecondary><CrossReferences><SourceEntity id="1009875" type="Company"><TargetEntity id="5035536114" type="organizationId">Fidelta doo</TargetEntity></SourceEntity><SourceEntity id="3771" type="ciIndication"><TargetEntity id="J84.112" type="ICD10"></TargetEntity><TargetEntity id="10021240" type="MEDDRA"></TargetEntity><TargetEntity id="D054990" type="MeSH"></TargetEntity><TargetEntity id="2032" type="ORPHANET"></TargetEntity><TargetEntity id="-1110748304" type="omicsDisease"></TargetEntity><TargetEntity id="289" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="3771">Idiopathic pulmonary fibrosis</Indication></IndicationsSecondary><ActionsSecondary><Action id="2953">Anti-inflammatory</Action><Action id="59620">Unspecified drug target</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2018-04-02T03:28:10.000Z</LastModificationDate><ChangeDateLast>2018-04-02T00:00:00.000Z</ChangeDateLast><AddedDate>2015-11-26T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;As no development has been reported for some time, this program is assumed to be discontinued.&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="1009875" linkType="Company"&gt;Fidelta&lt;/ulink&gt; was investigating a program of macrocyclic ligands  for the potential treatment of idiopathic pulmonary fibrosis (IPF).  In November 2015, lead identification was ongoing [&lt;ulink linkID="1715562" linkType="Reference"&gt;1715562&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Summary&gt;</value></Summary><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In November 2015, preclinical data were presented at the First RSC-SCI Fibrosis Disease Symposium, Slough, UK. One compound produced 66% inhibition of LPS challenge at 23 mg/kg and was active    at doses as low as 1 mg/kg. It had low oral bioavailability but was as effective as 100 mg/kg pirfenidone in the bleomycin fibrosis model. It reduced lung weight at 5 mg/kg bid and showed clear evidence of protective effects in histological studies. In a kidney fibrosis model, dose-dependent reduction of fibrosis, but not collagen deposition, at 1 to 5 mg/kg qd was observed. Five analogs prepared were shown to have better potency and pharmacokinetic properties, although oral potency remained lower than potency after intraperitoneal administration  [&lt;ulink linkID="1715562" linkType="Reference"&gt;1715562&lt;/ulink&gt;]. &lt;br&gt;&lt;/br&gt;&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1009875">Fidelta Ltd</Company><Country id="HR">Croatia</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="3771">Idiopathic pulmonary fibrosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-03-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1009875">Fidelta Ltd</Company><Country id="HR">Croatia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3771">Idiopathic pulmonary fibrosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-11-10T00:00:00.000Z</StatusDate><Source id="1715562" type="CONFERENCE"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=1715562" linkType="reference" linkID="1715562"&gt;1715562&lt;/ulink&gt;]
							</Description></ReasonForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug><Drug id="10001"><DrugName>T-794</DrugName><DrugSynonyms><Name><Value>T-94</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>T-794</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>135204-83-0</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="20315">Tanabe Seiyaku Co Ltd</CompanyOriginator><CompaniesSecondary><Company id="20289">Taisho Pharmaceutical Co Ltd</Company><Company id="20315">Tanabe Seiyaku Co Ltd</Company></CompaniesSecondary><CrossReferences><SourceEntity id="10001" type="Drug"><TargetEntity id="219317" type="siDrug">T-794</TargetEntity></SourceEntity><SourceEntity id="20289" type="Company"><TargetEntity id="4295876967" type="organizationId">Taisho Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="20315" type="Company"><TargetEntity id="4298123051" type="organizationId">Nipro ES Pharma Co Ltd</TargetEntity></SourceEntity><SourceEntity id="93" type="ciIndication"><TargetEntity id="10012378" type="MEDDRA"></TargetEntity><TargetEntity id="D003863" type="MeSH"></TargetEntity><TargetEntity id="-508468160" type="omicsDisease"></TargetEntity><TargetEntity id="53" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="254" type="Action"><TargetEntity id="449" type="Mechanism">MAO-A Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-01273" type="ciTarget"><TargetEntity id="175834908241283" type="siTarget">Amine oxidase [flavin-containing] A</TargetEntity><TargetEntity id="9251" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="93">Depression</Indication></IndicationsSecondary><ActionsPrimary><Action id="254">MAO A inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="2941">Antidepressant</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>N6A</Code><Name>ANTI-DEPRESSANTS AND MOOD STABILISERS</Name></Ephmra></EphmraCodes><LastModificationDate>2004-03-24T23:48:00.000Z</LastModificationDate><ChangeDateLast>2004-03-24T23:48:00.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;Tanabe is investigating &lt;ulink linkType="Drug" linkID="10001"&gt;T-794&lt;/ulink&gt;, a reversible selective inhibitor of monoamine oxidase-A (MAO-A), for the potential treatment of depression [&lt;ulink linkType="reference" linkID="175549"&gt;175549&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;It is effective in animal models of antidepressant activity, causing no weight loss, and is more potent and selective for MAO-A than &lt;ulink linkType="Drug" linkID="3644"&gt;moclobemide&lt;/ulink&gt; (qv) [&lt;ulink linkType="reference" linkID="175549"&gt;175549&lt;/ulink&gt;]. It also shows no evidence of cholinergic activity and a much reduced interaction with tyramine as compared to older MAO inhibitors [&lt;ulink linkType="reference" linkID="285978"&gt;285978&lt;/ulink&gt;]. The compound displayed an IC50 value of 3.8 nM against MAO-A [&lt;ulink linkType="reference" linkID="296669"&gt;296669&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Taisho is the licensee in Japan [&lt;ulink linkType="reference" linkID="251978"&gt;251978&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Compounds of this type are disclosed in EP-00425209.&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="20289">Taisho Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2001-08-24T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20315">Tanabe Seiyaku Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2001-08-24T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="20315">Tanabe Seiyaku Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="93">Depression</Indication><Source id="175549" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20289">Taisho Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="93">Depression</Indication><Source id="175549" type="SERIAL"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-01273"><Name>MAO A</Name><SwissprotNumbers><Swissprot>O18851</Swissprot><Swissprot>P21396</Swissprot><Swissprot>P21397</Swissprot><Swissprot>P21398</Swissprot><Swissprot>P58027</Swissprot><Swissprot>Q5NU32</Swissprot><Swissprot>Q5RE60</Swissprot><Swissprot>Q64133</Swissprot><Swissprot>Q6Q2J0</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug><Drug id="100010"><DrugName>lymphocyte expansion molecule stimulator gene therapy (cancer/viral infection), ImmunarT</DrugName><DrugSynonyms><Name><Value>lymphocyte expansion molecule stimulator gene therapy (cancer/viral infection), ImmunarT</Value></Name><Name><Value>LEM stimulator gene therapy (cancer/viral infection), ImmunarT</Value></Name></DrugSynonyms><CompanyOriginator id="1116520">ImmunarT Ltd</CompanyOriginator><CompaniesSecondary><Company id="1116520">ImmunarT Ltd</Company></CompaniesSecondary><CrossReferences><SourceEntity id="1116520" type="Company"><TargetEntity id="5047645483" type="organizationId">Immunart Ltd</TargetEntity></SourceEntity><SourceEntity id="344" type="ciIndication"><TargetEntity id="10047461" type="MEDDRA"></TargetEntity><TargetEntity id="D014777" type="MeSH"></TargetEntity><TargetEntity id="-1748727144" type="omicsDisease"></TargetEntity><TargetEntity id="854" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="991" type="Action"><TargetEntity id="4128" type="Mechanism">Flavivirus Guanylyl Transferase (NS5) Inhibitors</TargetEntity><TargetEntity id="1376" type="Mechanism">BR1 Expression Inhibitors</TargetEntity><TargetEntity id="4612" type="Mechanism">Drugs Targeting Human Immunodeficiency Virus 1 (HIV-1) Proteins</TargetEntity><TargetEntity id="3759" type="Mechanism">L Expression Inhibitors</TargetEntity><TargetEntity id="3575" type="Mechanism">Orthopoxvirus Egress Inhibitors</TargetEntity><TargetEntity id="2436" type="Mechanism">Viral Maturation Inhibitors</TargetEntity><TargetEntity id="5287" type="Mechanism">Drugs Targeting Influenza Virus Proteins</TargetEntity><TargetEntity id="3051" type="Mechanism">Viral Attachment Inhibitors</TargetEntity><TargetEntity id="4886" type="Mechanism">Drugs Targeting Hepatitis C Virus (HCV) Proteins</TargetEntity><TargetEntity id="3371" type="Mechanism">Drugs Acting on Influenza Virus Proton Channels</TargetEntity><TargetEntity id="3481" type="Mechanism">UL36 Expression Inhibitors</TargetEntity><TargetEntity id="3482" type="Mechanism">UL37 Expression Inhibitors</TargetEntity><TargetEntity id="3235" type="Mechanism">UL29 Expression Inhibitors</TargetEntity><TargetEntity id="5304" type="Mechanism">Drugs Targeting Rabies Virus Proteins</TargetEntity><TargetEntity id="1307" type="Mechanism">Viral Fusion Inhibitors</TargetEntity><TargetEntity id="4476" type="Mechanism">Anti-JC Polyomavirus Capsid Protein</TargetEntity><TargetEntity id="4479" type="Mechanism">Drugs Targeting JC Polyomavirus Proteins</TargetEntity><TargetEntity id="2893" type="Mechanism">Human T-Cell Leukemia Virus Type I (HTLV-I) Protease Inhibitors</TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="344">Viral infection</Indication><Indication id="651">Cancer</Indication></IndicationsSecondary><ActionsSecondary><Action id="1545">Anticancer</Action><Action id="4778">Gene therapy</Action><Action id="991">Antiviral</Action></ActionsSecondary><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="766">Parenteral formulation unspecified</Technology></Technologies><EphmraCodes><Ephmra><Code>J5</Code><Name>ANTIVIRALS FOR SYSTEMIC USE</Name></Ephmra></EphmraCodes><LastModificationDate>2018-04-02T03:27:44.000Z</LastModificationDate><ChangeDateLast>2018-04-02T00:00:00.000Z</ChangeDateLast><AddedDate>2015-11-26T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;As no development has been reported for some time, this program is assumed to be discontinued.&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="1116520" linkType="Company"&gt;ImmunarT&lt;/ulink&gt; was investigating a gene therapy that was designed to improve immunity by boosting the production of lymphocyte expansion molecule (LEM) that increases the proliferation of cytotoxic T cells, for the potential treatment of cancer and viral infection. In April 2015, the company planned to initiate human trials in three years. In May 2015, preclinical data were published [&lt;ulink linkID="1715692" linkType="Reference"&gt;1715692&lt;/ulink&gt;], [&lt;ulink linkID="1715424" linkType="Reference"&gt;1715424&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In April 2015, the company planned to initiate human trials in three years [&lt;ulink linkID="1715424" linkType="Reference"&gt;1715424&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In May 2015, preclinical data were published. Data demonstrated that LEM promoted antigen-dependent CD8+ T-cell proliferation, effector function, and memory cell generation in response to infection with lymphocytic choriomeningitis virus. Also, experiments in mice and human cells shown that the protein promotes the proliferation of cytotoxic T cells that kills cancer cells and cells infected with viruses [&lt;ulink linkID="1715692" linkType="Reference"&gt;1715692&lt;/ulink&gt;], [&lt;ulink linkID="1715424" linkType="Reference"&gt;1715424&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1116520">ImmunarT Ltd</Company><Country id="GB">UK</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="344">Viral infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-03-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1116520">ImmunarT Ltd</Company><Country id="GB">UK</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-03-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1116520">ImmunarT Ltd</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-01-23T00:00:00.000Z</StatusDate><Source id="1715692" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1116520">ImmunarT Ltd</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="344">Viral infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-01-23T00:00:00.000Z</StatusDate><Source id="1715692" type="SERIAL"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>2 references added [&lt;ulink url="utility.reference?i_reference_id=1715692" linkType="reference" linkID="1715692"&gt;1715692&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=1715424" linkType="reference" linkID="1715424"&gt;1715424&lt;/ulink&gt;]
							</Description></ReasonForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug><Drug id="100015"><DrugName>HOB-060</DrugName><DrugSynonyms><Name><Value>HOB-060</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>natural product (obesity), Hyundai Pharma</Value></Name></DrugSynonyms><CompanyOriginator id="22606">Hyundai Pharmaceutical</CompanyOriginator><CompaniesSecondary><Company id="22606">Hyundai Pharmaceutical</Company></CompaniesSecondary><CrossReferences><SourceEntity id="22606" type="Company"><TargetEntity id="4295881051" type="organizationId">Hyundai Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="238" type="ciIndication"><TargetEntity id="E66" type="ICD10"></TargetEntity><TargetEntity id="10029883" type="MEDDRA"></TargetEntity><TargetEntity id="D009765" type="MeSH"></TargetEntity><TargetEntity id="-1640888899" type="omicsDisease"></TargetEntity><TargetEntity id="985" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="238">Obesity</Indication></IndicationsSecondary><ActionsSecondary><Action id="59620">Unspecified drug target</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology><Technology id="1647">Natural product</Technology></Technologies><EphmraCodes><Ephmra><Code>A8</Code><Name>ANTIOBESITY PREPARATIONS, EXCLUDING DIETETICS</Name></Ephmra></EphmraCodes><LastModificationDate>2018-04-02T03:19:47.000Z</LastModificationDate><ChangeDateLast>2018-04-02T00:00:00.000Z</ChangeDateLast><AddedDate>2015-11-26T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;As no development has been reported for some time, this program is assumed to be discontinued.&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="22606" linkType="Company"&gt;Hyundai Pharma&lt;/ulink&gt; was investigating HOB-060, a natural product for the potential treatment of obesity. In November 2015, the drug was in preclinical development [&lt;ulink linkID="1710896" linkType="Reference"&gt;1710896&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="22606">Hyundai Pharmaceutical</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="238">Obesity</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-03-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="22606">Hyundai Pharmaceutical</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="238">Obesity</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-11-06T00:00:00.000Z</StatusDate><Source id="1710896" type="CORPORATE"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=1710896" linkType="reference" linkID="1710896"&gt;1710896&lt;/ulink&gt;]
							</Description></ReasonForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug><Drug id="100019"><DrugName>HOB-071</DrugName><DrugSynonyms><Name><Value>HOB-071</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>DPP-IV + ARB (diabetic hyperlipidemia), Hyundai Pharma</Value></Name></DrugSynonyms><CompanyOriginator id="22606">Hyundai Pharmaceutical</CompanyOriginator><CompaniesSecondary><Company id="22606">Hyundai Pharmaceutical</Company></CompaniesSecondary><CrossReferences><SourceEntity id="22606" type="Company"><TargetEntity id="4295881051" type="organizationId">Hyundai Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="175" type="ciIndication"><TargetEntity id="10062060" type="MEDDRA"></TargetEntity><TargetEntity id="D006949" type="MeSH"></TargetEntity><TargetEntity id="-1908196798" type="omicsDisease"></TargetEntity><TargetEntity id="971" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="64" type="Action"><TargetEntity id="3578" type="Mechanism">Anti-Angiotensin II</TargetEntity></SourceEntity><SourceEntity id="5537" type="Action"><TargetEntity id="5399" type="Mechanism">Dipeptidyl peptidase 4 (DPP4) antagonists</TargetEntity><TargetEntity id="3328" type="Mechanism">Anti-CD26 (Anti-Dipeptidyl Peptidase IV; DPPIV)</TargetEntity><TargetEntity id="415" type="Mechanism">Dipeptidyl Peptidase IV (CD26; DPP-IV; DP-IV) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-00618" type="ciTarget"><TargetEntity id="17367845618033" type="siTarget">Dipeptidyl peptidase 4</TargetEntity><TargetEntity id="8056" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="175">Hyperlipidemia</Indication></IndicationsSecondary><ActionsPrimary><Action id="64">Angiotensin II receptor antagonist</Action><Action id="5537">Dipeptidyl peptidase IV inhibitor</Action></ActionsPrimary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>C9C</Code><Name>ANGIOTENSIN-II ANTAGONISTS, PLAIN</Name></Ephmra></EphmraCodes><LastModificationDate>2018-04-02T03:20:11.000Z</LastModificationDate><ChangeDateLast>2018-04-02T00:00:00.000Z</ChangeDateLast><AddedDate>2015-11-26T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;As no development has been reported for some time, this program is assumed to be discontinued.&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="22606" linkType="Company"&gt;Hyundai Pharma&lt;/ulink&gt; was investigating HOB-071, a dipeptidyl peptidase-IV (DPP-IV) inhibitor and an angiotensin II receptor antagonist (ARB), for the potential treatment of diabetic hyperlipidemia [&lt;ulink linkID="1710896" linkType="Reference"&gt;1710896&lt;/ulink&gt;]. In November 2015, the program was in the discovery stage [&lt;ulink linkID="1710896" linkType="Reference"&gt;1710896&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="22606">Hyundai Pharmaceutical</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-03-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="22606">Hyundai Pharmaceutical</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-11-06T00:00:00.000Z</StatusDate><Source id="1710896" type="CORPORATE"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00139"><Name>Angiotensin II receptor</Name><SwissprotNumbers></SwissprotNumbers></Target><Target id="PTGT-00618"><Name>Dipeptidyl peptidase IV</Name><SwissprotNumbers><Swissprot>P14740</Swissprot><Swissprot>P22411</Swissprot><Swissprot>P27487</Swissprot><Swissprot>P28843</Swissprot><Swissprot>P81425</Swissprot><Swissprot>Q9N2I7</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=1710896" linkType="reference" linkID="1710896"&gt;1710896&lt;/ulink&gt;]
							</Description></ReasonForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug><Drug id="10002"><DrugName>Kamikihi-to</DrugName><DrugSynonyms><Name><Value>Kamikihi-to</Value></Name></DrugSynonyms><CompanyOriginator id="17636">Kanebo KK</CompanyOriginator><CompaniesSecondary><Company id="17636">Kanebo KK</Company></CompaniesSecondary><CrossReferences><SourceEntity id="10002" type="Drug"><TargetEntity id="220663" type="siDrug">Kamikihi-To</TargetEntity></SourceEntity><SourceEntity id="17636" type="Company"><TargetEntity id="5035523340" type="organizationId">Kaigan Bell Management Ltd</TargetEntity></SourceEntity><SourceEntity id="364" type="ciIndication"><TargetEntity id="10020388" type="MEDDRA"></TargetEntity><TargetEntity id="D020249" type="MeSH"></TargetEntity><TargetEntity id="-411582485" type="omicsDisease"></TargetEntity><TargetEntity id="558" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="442" type="ciIndication"><TargetEntity id="10058490" type="MEDDRA"></TargetEntity><TargetEntity id="D018496" type="MeSH"></TargetEntity><TargetEntity id="-1649545996" type="omicsDisease"></TargetEntity><TargetEntity id="4057" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="65" type="ciIndication"><TargetEntity id="D020521" type="MeSH"></TargetEntity><TargetEntity id="-1815339002" type="omicsDisease"></TargetEntity><TargetEntity id="93" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="364">Hormone deficiency</Indication><Indication id="442">Hyperoxia</Indication><Indication id="65">Stroke</Indication></IndicationsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2001-02-07T16:57:12.000Z</LastModificationDate><ChangeDateLast>2001-02-07T16:57:12.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;Kamihiki-to is an oriental herbal medicine which was being investigated by Kanebo for the treatment of stroke, hyperoxia and menopausal disorders [&lt;ulink linkType="reference" linkID="175613"&gt;175613&lt;/ulink&gt;]. However, no development has been reported by the company since 1997 [&lt;ulink linkType="reference" linkID="398050"&gt;398050&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Kamihiki-to ameliorated certain behavioral and physiological changes which occur in ovariectomized rats [&lt;ulink linkType="reference" linkID="175613"&gt;175613&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="17636">Kanebo KK</Company><Country id="JP">Japan</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="65">Stroke</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2001-02-06T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17636">Kanebo KK</Company><Country id="JP">Japan</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="364">Hormone deficiency</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2001-02-06T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17636">Kanebo KK</Company><Country id="JP">Japan</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="442">Hyperoxia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2001-02-06T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="17636">Kanebo KK</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="442">Hyperoxia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1995-09-01T00:00:00.000Z</StatusDate><Source id="175613" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17636">Kanebo KK</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="65">Stroke</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1995-09-01T00:00:00.000Z</StatusDate><Source id="175613" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17636">Kanebo KK</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="364">Hormone deficiency</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1995-09-01T00:00:00.000Z</StatusDate><Source id="175613" type="SERIAL"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>17 references added [&lt;ulink url="utility.reference?i_reference_id=176220" linkType="reference" linkID="176220"&gt;176220&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=176223" linkType="reference" linkID="176223"&gt;176223&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=176228" linkType="reference" linkID="176228"&gt;176228&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=176242" linkType="reference" linkID="176242"&gt;176242&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=176222" linkType="reference" linkID="176222"&gt;176222&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=176232" linkType="reference" linkID="176232"&gt;176232&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=176244" linkType="reference" linkID="176244"&gt;176244&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=176221" linkType="reference" linkID="176221"&gt;176221&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=176204" linkType="reference" linkID="176204"&gt;176204&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=176230" linkType="reference" linkID="176230"&gt;176230&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=176218" linkType="reference" linkID="176218"&gt;176218&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=176224" linkType="reference" linkID="176224"&gt;176224&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=176236" linkType="reference" linkID="176236"&gt;176236&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=398050" linkType="reference" linkID="398050"&gt;398050&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=176248" linkType="reference" linkID="176248"&gt;176248&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=175613" linkType="reference" linkID="175613"&gt;175613&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=176215" linkType="reference" linkID="176215"&gt;176215&lt;/ulink&gt;]
							</Description></ReasonForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug><Drug id="100020"><DrugName>HDDO-1604</DrugName><DrugSynonyms><Name><Value>HOB-075</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>HDDO-1604</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="22606">Hyundai Pharmaceutical</CompanyOriginator><CompaniesSecondary><Company id="22606">Hyundai Pharmaceutical</Company></CompaniesSecondary><CrossReferences><SourceEntity id="22606" type="Company"><TargetEntity id="4295881051" type="organizationId">Hyundai Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="90" type="ciIndication"><TargetEntity id="10012267" type="MEDDRA"></TargetEntity><TargetEntity id="D003704" type="MeSH"></TargetEntity><TargetEntity id="-1720562635" type="omicsDisease"></TargetEntity><TargetEntity id="100" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="93" type="ciIndication"><TargetEntity id="10012378" type="MEDDRA"></TargetEntity><TargetEntity id="D003863" type="MeSH"></TargetEntity><TargetEntity id="-508468160" type="omicsDisease"></TargetEntity><TargetEntity id="53" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3" type="Action"><TargetEntity id="235" type="Mechanism">5-HT Reuptake Inhibitors</TargetEntity></SourceEntity><SourceEntity id="18" type="Action"><TargetEntity id="381" type="Mechanism">Angiotensin-I Converting Enzyme (ACE) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-00039" type="ciTarget"><TargetEntity id="55189613116363" type="siTarget">Angiotensin-converting enzyme</TargetEntity><TargetEntity id="2465" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="90">Dementia</Indication><Indication id="93">Depression</Indication></IndicationsSecondary><ActionsPrimary><Action id="18">ACE inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="2941">Antidepressant</Action><Action id="3">5-HT uptake inhibitor</Action></ActionsSecondary><Technologies><Technology id="175">Drug combination</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>C9A</Code><Name>ACE INHIBITORS, PLAIN</Name></Ephmra><Ephmra><Code>N6A</Code><Name>ANTI-DEPRESSANTS AND MOOD STABILISERS</Name></Ephmra><Ephmra><Code>N6A4</Code><Name>SSRI antidepressants</Name></Ephmra></EphmraCodes><LastModificationDate>2019-04-05T17:15:59.000Z</LastModificationDate><ChangeDateLast>2017-07-24T00:00:00.000Z</ChangeDateLast><AddedDate>2015-11-26T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="22606" linkType="Company"&gt;Hyundai Pharma&lt;/ulink&gt; was investigating HDDO-1604 (previously HOB-075), a combination of an angiotensin converting enzyme (ACE) inhibitor and a selective serotonin re-uptake inhibitor (SSRI), for the potential treatment of dementia including Alzheimer's  affecting elderly people [&lt;ulink linkID="1710896" linkType="Reference"&gt;1710896&lt;/ulink&gt;], [&lt;ulink linkID="1946873" linkType="Reference"&gt;1946873&lt;/ulink&gt;]. In November 2015, the program was in preclinical development [&lt;ulink linkID="1710896" linkType="Reference"&gt;1710896&lt;/ulink&gt;]; by February 2017, toxicity and PK studies had been completed  [&lt;ulink linkID="1905186" linkType="Reference"&gt;1905186&lt;/ulink&gt;]. However, in November 2018, the program was no longer listed as one being in development [&lt;ulink linkID="2029123" linkType="Reference"&gt;2029123&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;The program was previously being evaluated for depression  [&lt;ulink linkID="1710896" linkType="Reference"&gt;1710896&lt;/ulink&gt;]. However, by February 2017, the focus had become dementia including Alzheimer's [&lt;ulink linkID="1905186" linkType="Reference"&gt;1905186&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="22606">Hyundai Pharmaceutical</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="90">Dementia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-11-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22606">Hyundai Pharmaceutical</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-02-28T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="22606">Hyundai Pharmaceutical</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-11-06T00:00:00.000Z</StatusDate><Source id="1710896" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22606">Hyundai Pharmaceutical</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="90">Dementia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-11-06T00:00:00.000Z</StatusDate><Source id="1710896" type="CORPORATE"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00039"><Name>ACE</Name><SwissprotNumbers><Swissprot>P09470</Swissprot><Swissprot>P12820</Swissprot><Swissprot>P12821</Swissprot><Swissprot>P12822</Swissprot><Swissprot>P47820</Swissprot><Swissprot>Q10714</Swissprot><Swissprot>Q10715</Swissprot><Swissprot>Q10751</Swissprot><Swissprot>Q50JE5</Swissprot><Swissprot>Q6Q4G4</Swissprot><Swissprot>Q9GLN7</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug><Drug id="100021"><DrugName>tranexamic acid (topical, melasma), Hyundai</DrugName><DrugNamesKey><Name id="156621">tranexamic acid</Name></DrugNamesKey><DrugSynonyms><Name><Value>tranexamic acid</Value><Types><Type>INN</Type></Types></Name><Name><Value>tranexamic acid (topical, melasma), Hyundai</Value></Name><Name><Value>HTB-003</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>HDDT-1603</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>1197-18-8</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="22606">Hyundai Pharmaceutical</CompanyOriginator><CompaniesSecondary><Company id="22606">Hyundai Pharmaceutical</Company></CompaniesSecondary><CrossReferences><SourceEntity id="22606" type="Company"><TargetEntity id="4295881051" type="organizationId">Hyundai Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="2011" type="ciIndication"><TargetEntity id="L81.1" type="ICD10"></TargetEntity><TargetEntity id="H02.71" type="ICD10"></TargetEntity><TargetEntity id="10008570" type="MEDDRA"></TargetEntity><TargetEntity id="3491" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1571" type="Action"><TargetEntity id="1137" type="Mechanism">Plasmin Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-01583" type="ciTarget"><TargetEntity id="17366577953403" type="siTarget">Plasminogen</TargetEntity><TargetEntity id="-853568211" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="2011">Melasma</Indication></IndicationsSecondary><ActionsPrimary><Action id="1571">Plasmin inhibitor</Action></ActionsPrimary><Technologies><Technology id="762">Small molecule therapeutic</Technology><Technology id="611">Dermatological formulation</Technology></Technologies><LastModificationDate>2018-01-23T16:11:28.000Z</LastModificationDate><ChangeDateLast>2017-07-24T00:00:00.000Z</ChangeDateLast><AddedDate>2015-11-26T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="22606" linkType="Company"&gt;Hyundai Pharma&lt;/ulink&gt; was developing HDDT-1603 (previously HTB-003), a topical formulation of the plasmin inhibitor tranexamic acid, incorporating the company's Transdermal Accelerating Technology, for the potential treatment of melasma [&lt;ulink linkID="1710896" linkType="Reference"&gt;1710896&lt;/ulink&gt;], [&lt;ulink linkID="1723864" linkType="Reference"&gt;1723864&lt;/ulink&gt;]. In November 2015, the drug was in phase II development [&lt;ulink linkID="1710896" linkType="Reference"&gt;1710896&lt;/ulink&gt;]. However, the program was no longer listed on Hyundai's July 2017 pipeline [&lt;ulink linkID="1946873" linkType="Reference"&gt;1946873&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="22606">Hyundai Pharmaceutical</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="2011">Melasma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-07-14T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="22606">Hyundai Pharmaceutical</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2011">Melasma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-09-28T00:00:00.000Z</StatusDate><Source id="1723864" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22606">Hyundai Pharmaceutical</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2011">Melasma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-11-06T00:00:00.000Z</StatusDate><Source id="1710896" type="CORPORATE"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-01583"><Name>Plasmin</Name><SwissprotNumbers><Swissprot>P00747</Swissprot><Swissprot>P06867</Swissprot><Swissprot>P06868</Swissprot><Swissprot>P20918</Swissprot><Swissprot>P80009</Swissprot><Swissprot>P80010</Swissprot><Swissprot>Q01177</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><PatentFamilies><PatentFamily id="2811796" number="WO-2014163338" title="Composition for external use preparation with improved transdermal permeability"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hyundai Pharmaceutical" id="22606"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug><Drug id="100022"><DrugName>HTB-005</DrugName><DrugSynonyms><Name><Value>HTB-005</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="22606">Hyundai Pharmaceutical</CompanyOriginator><CompaniesSecondary><Company id="22606">Hyundai Pharmaceutical</Company></CompaniesSecondary><CrossReferences><SourceEntity id="22606" type="Company"><TargetEntity id="4295881051" type="organizationId">Hyundai Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="13" type="ciIndication"><TargetEntity id="10001760" type="MEDDRA"></TargetEntity><TargetEntity id="D000505" type="MeSH"></TargetEntity><TargetEntity id="-1648289448" type="omicsDisease"></TargetEntity><TargetEntity id="469" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="13">Alopecia</Indication></IndicationsSecondary><ActionsSecondary><Action id="59620">Unspecified drug target</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2018-04-02T03:20:48.000Z</LastModificationDate><ChangeDateLast>2018-04-02T00:00:00.000Z</ChangeDateLast><AddedDate>2015-11-26T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;As no development has been reported for some time, this program is assumed to be discontinued.&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="22606" linkType="Company"&gt;Hyundai Pharma&lt;/ulink&gt; was investigating HTB-005,  for the potential treatment of alopecia. In November 2015, the drug was in preclinical development [&lt;ulink linkID="1710896" linkType="Reference"&gt;1710896&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="22606">Hyundai Pharmaceutical</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="13">Alopecia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-03-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="22606">Hyundai Pharmaceutical</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="13">Alopecia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-11-06T00:00:00.000Z</StatusDate><Source id="1710896" type="CORPORATE"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=1710896" linkType="reference" linkID="1710896"&gt;1710896&lt;/ulink&gt;]
							</Description></ReasonForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug><Drug id="100023"><DrugName>HTB-006</DrugName><DrugSynonyms><Name><Value>HTB-006</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="22606">Hyundai Pharmaceutical</CompanyOriginator><CompaniesSecondary><Company id="22606">Hyundai Pharmaceutical</Company></CompaniesSecondary><CrossReferences><SourceEntity id="22606" type="Company"><TargetEntity id="4295881051" type="organizationId">Hyundai Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="238" type="ciIndication"><TargetEntity id="E66" type="ICD10"></TargetEntity><TargetEntity id="10029883" type="MEDDRA"></TargetEntity><TargetEntity id="D009765" type="MeSH"></TargetEntity><TargetEntity id="-1640888899" type="omicsDisease"></TargetEntity><TargetEntity id="985" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="238">Obesity</Indication></IndicationsSecondary><ActionsSecondary><Action id="59620">Unspecified drug target</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>A8</Code><Name>ANTIOBESITY PREPARATIONS, EXCLUDING DIETETICS</Name></Ephmra></EphmraCodes><LastModificationDate>2018-04-02T03:21:07.000Z</LastModificationDate><ChangeDateLast>2018-04-02T00:00:00.000Z</ChangeDateLast><AddedDate>2015-11-26T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;As no development has been reported for some time, this program is assumed to be discontinued.&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="22606" linkType="Company"&gt;Hyundai Pharma&lt;/ulink&gt; was investigating HTB-006,  for the potential treatment of obesity. In November 2015, the drug was in preclinical development [&lt;ulink linkID="1710896" linkType="Reference"&gt;1710896&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="22606">Hyundai Pharmaceutical</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="238">Obesity</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-03-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="22606">Hyundai Pharmaceutical</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="238">Obesity</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-11-06T00:00:00.000Z</StatusDate><Source id="1710896" type="CORPORATE"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=1710896" linkType="reference" linkID="1710896"&gt;1710896&lt;/ulink&gt;]
							</Description></ReasonForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug><Drug id="100025"><DrugName>phosphatidylethanolamine inhibitors (viral infections), Scripps Florida</DrugName><DrugSynonyms><Name><Value>phosphatidylethanolamine inhibitors (viral infections), Scripps Florida</Value></Name></DrugSynonyms><CompanyOriginator id="1111131">Scripps Florida</CompanyOriginator><CompaniesSecondary><Company id="1111131">Scripps Florida</Company></CompaniesSecondary><CrossReferences><SourceEntity id="344" type="ciIndication"><TargetEntity id="10047461" type="MEDDRA"></TargetEntity><TargetEntity id="D014777" type="MeSH"></TargetEntity><TargetEntity id="-1748727144" type="omicsDisease"></TargetEntity><TargetEntity id="854" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="991" type="Action"><TargetEntity id="3235" type="Mechanism">UL29 Expression Inhibitors</TargetEntity><TargetEntity id="4612" type="Mechanism">Drugs Targeting Human Immunodeficiency Virus 1 (HIV-1) Proteins</TargetEntity><TargetEntity id="2893" type="Mechanism">Human T-Cell Leukemia Virus Type I (HTLV-I) Protease Inhibitors</TargetEntity><TargetEntity id="5304" type="Mechanism">Drugs Targeting Rabies Virus Proteins</TargetEntity><TargetEntity id="3759" type="Mechanism">L Expression Inhibitors</TargetEntity><TargetEntity id="3482" type="Mechanism">UL37 Expression Inhibitors</TargetEntity><TargetEntity id="3371" type="Mechanism">Drugs Acting on Influenza Virus Proton Channels</TargetEntity><TargetEntity id="1307" type="Mechanism">Viral Fusion Inhibitors</TargetEntity><TargetEntity id="5287" type="Mechanism">Drugs Targeting Influenza Virus Proteins</TargetEntity><TargetEntity id="3575" type="Mechanism">Orthopoxvirus Egress Inhibitors</TargetEntity><TargetEntity id="2436" type="Mechanism">Viral Maturation Inhibitors</TargetEntity><TargetEntity id="4476" type="Mechanism">Anti-JC Polyomavirus Capsid Protein</TargetEntity><TargetEntity id="3481" type="Mechanism">UL36 Expression Inhibitors</TargetEntity><TargetEntity id="4128" type="Mechanism">Flavivirus Guanylyl Transferase (NS5) Inhibitors</TargetEntity><TargetEntity id="4886" type="Mechanism">Drugs Targeting Hepatitis C Virus (HCV) Proteins</TargetEntity><TargetEntity id="1376" type="Mechanism">BR1 Expression Inhibitors</TargetEntity><TargetEntity id="4479" type="Mechanism">Drugs Targeting JC Polyomavirus Proteins</TargetEntity><TargetEntity id="3051" type="Mechanism">Viral Attachment Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="344">Viral infection</Indication></IndicationsSecondary><ActionsSecondary><Action id="59620">Unspecified drug target</Action><Action id="991">Antiviral</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology><Technology id="66">Antibiotic</Technology></Technologies><EphmraCodes><Ephmra><Code>J5</Code><Name>ANTIVIRALS FOR SYSTEMIC USE</Name></Ephmra></EphmraCodes><LastModificationDate>2018-04-02T03:30:55.000Z</LastModificationDate><ChangeDateLast>2018-04-02T00:00:00.000Z</ChangeDateLast><AddedDate>2015-11-26T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;As no development has been reported for some time, this program is assumed to be discontinued.&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="1111131" linkType="Company"&gt;Scripps Florida&lt;/ulink&gt; was investigating phosphatidylethanolamine inhibitors for the potential treatment of viral infections, including dengue, west Nile and ebola infections [&lt;ulink linkID="1715917" linkType="Reference"&gt;1715917&lt;/ulink&gt;], [&lt;ulink linkID="1715792" linkType="Reference"&gt;1715792&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In November 2015, data were published.   Data demonstrated that    phosphatidylethanolamine plays a key role in TIM1-mediated virus entry which suggested that disrupting phosphatidylethanolamine association with phosphatidylserine receptors shows promising broad-spectrum antiviral strategy [&lt;ulink linkID="1715917" linkType="Reference"&gt;1715917&lt;/ulink&gt;], [&lt;ulink linkID="1715792" linkType="Reference"&gt;1715792&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1111131">Scripps Florida</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="344">Viral infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-03-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1111131">Scripps Florida</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="344">Viral infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-11-02T00:00:00.000Z</StatusDate><Source id="1715917" type="SERIAL"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>2 references added [&lt;ulink url="utility.reference?i_reference_id=1715792" linkType="reference" linkID="1715792"&gt;1715792&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=1715917" linkType="reference" linkID="1715917"&gt;1715917&lt;/ulink&gt;]
							</Description></ReasonForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Deal Summary Added/Updated</Reason><Description>Deal summary added/updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="20516">US Government</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="21102">Scripps Research Institute</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="13">Drug - Funding</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="157366" title="NIAID to award Scripps Florida funding for the development of phosphatidylethanolamine inhibitors against viral infections"></Deal></Deals><hasSWOTs>N</hasSWOTs></Drug><Drug id="100028"><DrugName>human insulin biosimilar, Marvel Lifesciences</DrugName><DrugNamesKey><Name id="43071376">Solumarv</Name></DrugNamesKey><DrugSynonyms><Name><Value>Solumarv</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>human insulin biosimilar, Marvel Lifesciences</Value></Name></DrugSynonyms><CompanyOriginator id="1071528">Marvel Lifesciences Ltd</CompanyOriginator><CompaniesSecondary><Company id="1071528">Marvel Lifesciences Ltd</Company></CompaniesSecondary><CrossReferences><SourceEntity id="836" type="ciIndication"><TargetEntity id="E10" type="ICD10"></TargetEntity><TargetEntity id="10067584" type="MEDDRA"></TargetEntity><TargetEntity id="D003922" type="MeSH"></TargetEntity><TargetEntity id="-686743471" type="omicsDisease"></TargetEntity><TargetEntity id="507" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="837" type="ciIndication"><TargetEntity id="E11" type="ICD10"></TargetEntity><TargetEntity id="10067585" type="MEDDRA"></TargetEntity><TargetEntity id="D003924" type="MeSH"></TargetEntity><TargetEntity id="-1888632793" type="omicsDisease"></TargetEntity><TargetEntity id="509" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="400" type="Action"><TargetEntity id="1034" type="Mechanism">Insulin Receptor Agonists</TargetEntity><TargetEntity id="609" type="Mechanism">Insulin Secretagogues</TargetEntity></SourceEntity><SourceEntity id="399" type="Action"><TargetEntity id="884" type="Mechanism">Glucose Lowering Agents</TargetEntity></SourceEntity><SourceEntity id="PTGT-04991" type="ciTarget"><TargetEntity id="129209803836303" type="siTarget">Insulin</TargetEntity><TargetEntity id="1003" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="PR">Pre-registration</PhaseTerminated><IndicationsSecondary><Indication id="836">Insulin dependent diabetes</Indication><Indication id="837">Non-insulin dependent diabetes</Indication></IndicationsSecondary><ActionsPrimary><Action id="23014">Insulin ligand</Action><Action id="400">Insulin receptor agonist</Action></ActionsPrimary><ActionsSecondary><Action id="38212">Human insulin intermediate acting product</Action><Action id="399">Hypoglycemic agent</Action></ActionsSecondary><Technologies><Technology id="648">Intravenous formulation</Technology><Technology id="746">Solution</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="647">Subcutaneous formulation</Technology></Technologies><EphmraCodes><Ephmra><Code>A10C2</Code><Name>Human insulins and analogues, intermediate-acting</Name></Ephmra><Ephmra><Code>A10C</Code><Name>HUMAN INSULINS AND ANALOGUES</Name></Ephmra></EphmraCodes><LastModificationDate>2018-07-25T13:55:27.000Z</LastModificationDate><ChangeDateLast>2018-07-26T00:00:00.000Z</ChangeDateLast><AddedDate>2015-11-26T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1071528" linkType="Company"&gt;Marvel Lifesciences&lt;/ulink&gt; was developing Solumarv, a biosimilar version of &lt;ulink linkID="47499" linkType="Drug"&gt;Humulin S&lt;/ulink&gt;, for the potential treatment of diabetes mellitus. In December 2011, the company filed an MAA with the EMA [&lt;ulink linkID="1715941" linkType="Reference"&gt;1715941&lt;/ulink&gt;]. In November 2015, the CHMP of the EMA adopted a negative opinion for Solumarv [&lt;ulink linkID="1715185" linkType="Reference"&gt;1715185&lt;/ulink&gt;]; later that month, 	CHMP recommended the refusal of the MAA [&lt;ulink linkID="1716050" linkType="Reference"&gt;1716050&lt;/ulink&gt;]. However, by May 2017, no further development had been reported.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In December 2011, the company filed an MAA with the EMA. In November 2012, the company withdrawn its MAA in order to have sufficient time to repeat and submit bioequivalence, pharmacokinetics and pharmacodynamics data in order to comply with the planned new insulin guideline at a validated CRO [&lt;ulink linkID="1715941" linkType="Reference"&gt;1715941&lt;/ulink&gt;]. In November 2015, the CHMP of the EMA adopted a negative opinion for Solumarv as the company had not provided sufficient detail regarding the manufacturing process of Solumarv [&lt;ulink linkID="1715185" linkType="Reference"&gt;1715185&lt;/ulink&gt;]; later that month, 	CHMP recommended the refusal of the MAA. To support its MAA, the company included results of studies in helathy subjects that showed Solumarv was similar to Humulin S in terms of biological activity and pharmacokinetics of the drug. In addition, data were presented from two additional studies in type 1 and 2 diabetes patients  that compared the safety and effectiveness of Solumarv and Humulin S. At that time,  EMA stated that the company would request a re-examination of the opinion within 15 days of receipt of notification of the negative opinion [&lt;ulink linkID="1716050" linkType="Reference"&gt;1716050&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In June 2016, clinical data from two double blind, crossover studies (study 1 and 2) were presented at the 76th ADA Scientific Sessions in New Orleans, LA. . Subjects (n = 81) in study-1 were randomized to receive 0.3 units/kg solumarv or humulin S and study-2 patients received 0.6 units/kg solumarv or humulin basal injections (sc). The AUC (insulin 0 to 12 h) and C insulin max in study-1 were 347munits.h/l and 68.6 microunits/l in solumarv treated arm, respectively, and in humulin S treated arm was 342 munits.h/l and 63.4 microunits/l, respectively. The AUC (insulin 0 to 12 h) and C insulin max in study-2 were 459 munits.h/l and 28.1 microunits/l in solumarv treated arm, respectively, and in huminsulin basal treated arm was 415 munits.h/l and 28.2 microunits/l, respectively [&lt;ulink linkID="1773469" linkType="Reference"&gt;1773469&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1071528">Marvel Lifesciences Ltd</Company><Country id="EU">EU</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-05-20T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1071528">Marvel Lifesciences Ltd</Company><Country id="EU">EU</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="836">Insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-05-20T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1071528">Marvel Lifesciences Ltd</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-12-05T00:00:00.000Z</StatusDate><Source id="1715941" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1071528">Marvel Lifesciences Ltd</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="836">Insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-12-05T00:00:00.000Z</StatusDate><Source id="1715941" type="PR"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-01028"><Name>Insulin receptor</Name><SwissprotNumbers><Swissprot>P06213</Swissprot><Swissprot>P09208</Swissprot><Swissprot>P15127</Swissprot><Swissprot>P15208</Swissprot><Swissprot>Q28516</Swissprot><Swissprot>Q93105</Swissprot></SwissprotNumbers></Target><Target id="PTGT-04991"><Name>Insulin ligand</Name><SwissprotNumbers><Swissprot>O73727</Swissprot><Swissprot>P01308</Swissprot><Swissprot>P01310</Swissprot><Swissprot>P01311</Swissprot><Swissprot>P01313</Swissprot><Swissprot>P01314</Swissprot><Swissprot>P01315</Swissprot><Swissprot>P01316</Swissprot><Swissprot>P01317</Swissprot><Swissprot>P01318</Swissprot><Swissprot>P01319</Swissprot><Swissprot>P01320</Swissprot><Swissprot>P01321</Swissprot><Swissprot>P01324</Swissprot><Swissprot>P01327</Swissprot><Swissprot>P01328</Swissprot><Swissprot>P01329</Swissprot><Swissprot>P01330</Swissprot><Swissprot>P01331</Swissprot><Swissprot>P01333</Swissprot><Swissprot>P01334</Swissprot><Swissprot>P01335</Swissprot><Swissprot>P01336</Swissprot><Swissprot>P01340</Swissprot><Swissprot>P01342</Swissprot><Swissprot>P04667</Swissprot><Swissprot>P06306</Swissprot><Swissprot>P07453</Swissprot><Swissprot>P09476</Swissprot><Swissprot>P09477</Swissprot><Swissprot>P0C236</Swissprot><Swissprot>P12703</Swissprot><Swissprot>P12704</Swissprot><Swissprot>P12705</Swissprot><Swissprot>P12708</Swissprot><Swissprot>P13190</Swissprot><Swissprot>P17715</Swissprot><Swissprot>P18109</Swissprot><Swissprot>P21563</Swissprot><Swissprot>P29335</Swissprot><Swissprot>P30406</Swissprot><Swissprot>P30407</Swissprot><Swissprot>P30410</Swissprot><Swissprot>P41522</Swissprot><Swissprot>P42633</Swissprot><Swissprot>P51463</Swissprot><Swissprot>P67968</Swissprot><Swissprot>P67969</Swissprot><Swissprot>P67970</Swissprot><Swissprot>P67971</Swissprot><Swissprot>P67972</Swissprot><Swissprot>P67973</Swissprot><Swissprot>P67974</Swissprot><Swissprot>P68243</Swissprot><Swissprot>P68245</Swissprot><Swissprot>P68987</Swissprot><Swissprot>P68988</Swissprot><Swissprot>P68989</Swissprot><Swissprot>P68990</Swissprot><Swissprot>P68991</Swissprot><Swissprot>P68992</Swissprot><Swissprot>P69045</Swissprot><Swissprot>P69046</Swissprot><Swissprot>P69047</Swissprot><Swissprot>P69048</Swissprot><Swissprot>P81025</Swissprot><Swissprot>P81423</Swissprot><Swissprot>P81881</Swissprot><Swissprot>Q62587</Swissprot><Swissprot>Q6YK33</Swissprot><Swissprot>Q8HXV2</Swissprot><Swissprot>Q91XI3</Swissprot><Swissprot>Q98TA8</Swissprot><Swissprot>Q9TQY7</Swissprot><Swissprot>Q9W7R2</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug><Drug id="10003"><DrugName>SDZ-MAR-327</DrugName><DrugSynonyms><Name><Value>SDZ-MAR-327</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>MAR-327</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>202075-96-5</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="23137">Novartis AG</CompanyOriginator><CompaniesSecondary><Company id="23137">Novartis AG</Company><Company id="24513">Sandoz AB</Company><Company id="24572">Sandoz Pharma Ltd</Company></CompaniesSecondary><CrossReferences><SourceEntity id="10003" type="Drug"><TargetEntity id="193864" type="siDrug">SDZ-MAR-327</TargetEntity></SourceEntity><SourceEntity id="23137" type="Company"><TargetEntity id="4295890628" type="organizationId">Novartis AG</TargetEntity></SourceEntity><SourceEntity id="24513" type="Company"><TargetEntity id="5035750487" type="organizationId">Sandoz AB</TargetEntity></SourceEntity><SourceEntity id="299" type="ciIndication"><TargetEntity id="F20" type="ICD10"></TargetEntity><TargetEntity id="10039626" type="MEDDRA"></TargetEntity><TargetEntity id="D012559" type="MeSH"></TargetEntity><TargetEntity id="-729613619" type="omicsDisease"></TargetEntity><TargetEntity id="65" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="6" type="Action"><TargetEntity id="220" type="Mechanism">5-HT1A Receptor Agonists</TargetEntity></SourceEntity><SourceEntity id="148" type="Action"><TargetEntity id="124" type="Mechanism">Dopamine D1 Antagonists</TargetEntity></SourceEntity><SourceEntity id="149" type="Action"><TargetEntity id="131" type="Mechanism">Dopamine D2 Agonists</TargetEntity></SourceEntity><SourceEntity id="13" type="Action"><TargetEntity id="948" type="Mechanism">5-HT2 Antagonists</TargetEntity></SourceEntity><SourceEntity id="PTGT-00011" type="ciTarget"><TargetEntity id="100215858133503" type="siTarget">5-hydroxytryptamine receptor 1A</TargetEntity><TargetEntity id="4469" type="omicsTarget"></TargetEntity></SourceEntity><SourceEntity id="PTGT-00632" type="ciTarget"><TargetEntity id="18259311118123" type="siTarget">D(1A) dopamine receptor</TargetEntity><TargetEntity id="943" type="omicsTarget"></TargetEntity></SourceEntity><SourceEntity id="PTGT-00633" type="ciTarget"><TargetEntity id="80088336218133" type="siTarget">D(2) dopamine receptor</TargetEntity><TargetEntity id="8168" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="299">Schizophrenia</Indication></IndicationsSecondary><ActionsPrimary><Action id="148">Dopamine D1 receptor antagonist</Action><Action id="6">5-HT 1a receptor agonist</Action><Action id="149">Dopamine D2 receptor agonist</Action><Action id="13">5-HT 2 receptor antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="2943">Antipsychotic</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>N5A</Code><Name>ANTIPSYCHOTICS</Name></Ephmra></EphmraCodes><LastModificationDate>2017-08-31T03:33:02.000Z</LastModificationDate><ChangeDateLast>2009-03-26T10:43:39.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="23137" linkType="Company"&gt;Novartis&lt;/ulink&gt; (formerly Sandoz) has discontinued development of &lt;ulink linkID="10003" linkType="Drug"&gt;SDZ-MAR-327&lt;/ulink&gt;, an ergoline derivative, for the potential treatment of schizophrenia [&lt;ulink linkID="347270" linkType="reference"&gt;347270&lt;/ulink&gt;], [&lt;ulink linkID="347827" linkType="reference"&gt;347827&lt;/ulink&gt;]. Development of the compound, which had reached phase II trials, was discontinued in 1998 [&lt;ulink linkID="189950" linkType="reference"&gt;189950&lt;/ulink&gt;], [&lt;ulink linkID="244117" linkType="reference"&gt;244117&lt;/ulink&gt;], [&lt;ulink linkID="347270" linkType="reference"&gt;347270&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Phase II clinical trials were underway by October 1995 and, at this time, Sandoz was expecting to have the results by mid-1996 and to then start phase III trials [&lt;ulink linkID="189950" linkType="reference"&gt;189950&lt;/ulink&gt;]. However, phase II trials were ongoing in April 1997 [&lt;ulink linkID="244117" linkType="reference"&gt;244117&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In a double-blind maximum tolerated dose clinical trial, completed by 1995, 18 hospitalized schizophrenic patients were randomly assigned to placebo, haloperidol or &lt;ulink linkID="10003" linkType="Drug"&gt;SDZ-MAR-327&lt;/ulink&gt;. Patients were scanned at baseline on placebo and then at low (150 to 200 mg/day) and moderate doses (300 to 400 mg/day) of &lt;ulink linkID="10003" linkType="Drug"&gt;SDZ-MAR-327&lt;/ulink&gt;. The patients in the &lt;ulink linkID="10003" linkType="Drug"&gt;SDZ-MAR-327&lt;/ulink&gt; group had a mean age of 35. The metabolic differences were considerable, with the 300 to 400 mg/kg dose decreasing the metabolism in the cortex while sparing the striatum [&lt;ulink linkID="190212" linkType="reference"&gt;190212&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The compound has activity at 5-HT1A and 5-HT2 receptors, is a partial agonist of dopamine D2 receptors, and an antagonist of D1 receptors [&lt;ulink linkID="175550" linkType="reference"&gt;175550&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><ExpertReview>&lt;para&gt;&lt;subtitle&gt;&lt;ulink linkType="Drug" linkID="10003"&gt;SDZ-MAR-327&lt;/ulink&gt;
&lt;/subtitle&gt;Dr Antonio Preti, Institute of Medical Pharmacology, University of Rome&lt;br/&gt;6 May 1999&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Introduction&lt;/subtitle&gt;Dopamine, one of the first substances to be characterized as a neurotransmitter, has received large coverage as a target of pharmacological interventions aimed at the treatment of neuropsychiatric disorders. Its role in mental disorders, such as mania, depression and schizophrenia, as well as in neurological disorders such as Parkinson's disease is well known [&lt;ulink linkType="reference" linkID="333993"&gt;333993&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="333994"&gt;333994&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="333995"&gt;333995&lt;/ulink&gt;]. The role of dopamine in reward and drug abuse is another field of intensive research [&lt;ulink linkType="reference" linkID="325824"&gt;325824&lt;/ulink&gt;]. However, dispute exists on the most appropriate way to compensate the dopamine imbalance thought to contribute to the symptoms of many neuropsychiatric disorders.&lt;/para&gt;&lt;para&gt;Antidopaminergic drugs, for example, are the gold standard in the treatment of schizophrenia and related psychoses [&lt;ulink linkType="reference" linkID="1910"&gt;1910&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="316701"&gt;316701&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="316762"&gt;316762&lt;/ulink&gt;]. Their efficacy is related to their actions at dopamine D2 receptors, although more recent compounds also show activity at 5-HT receptors [&lt;ulink linkType="reference" linkID="1910"&gt;1910&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="316701"&gt;316701&lt;/ulink&gt;]. However, several weeks or even months are often needed to see the full therapeutic effect [&lt;ulink linkType="reference" linkID="316701"&gt;316701&lt;/ulink&gt;]. Moreover, about 20 % of patients respond minimally or not at all to the available drugs [&lt;ulink linkType="reference" linkID="1910"&gt;1910&lt;/ulink&gt;]. The so-called negative symptoms (inhibition, apathy, poor motivation and lack of initiative), seem to respond particularly poorly  to classical antidopaminergic drugs. This frequently reported clinical failure raises doubts about the nature of dopamine imbalance in schizophrenia [&lt;ulink linkType="reference" linkID="282960"&gt;282960&lt;/ulink&gt;]. More recent hypotheses concerning the role of dopamine in schizophrenia, support a differential involvement of the diverse brain dopaminergic circuits [&lt;ulink linkType="reference" linkID="282960"&gt;282960&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="325826"&gt;325826&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="325827"&gt;325827&lt;/ulink&gt;]. In particular, mesolimbic and fronto-cortical dopaminergic pathways seem to have specific and different roles in the control of behavior [&lt;ulink linkType="reference" linkID="282960"&gt;282960&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="325826"&gt;325826&lt;/ulink&gt;]. Some studies indicate that dopamine activity in the pre-frontal area would exert an inhibitory effect on sub-cortical dopaminergic functions. In schizophrenia, dopaminergic hypofunction in fronto-cortical regions is thought to correlate with volitional deficits, whereas the hyperactivity in dopamine mesolimbic circuits would explain the hallucinations and delusions typically observed in the acute phase of schizophrenia [&lt;ulink linkType="reference" linkID="86634"&gt;86634&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="282960"&gt;282960&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Unwanted side effects associated with treatment are another problem in the therapy of schizophrenia. Side effects associated with antipsychotic drugs impair the quality of life of patients and reduce compliance to prescribed drugs [&lt;ulink linkType="reference" linkID="1910"&gt;1910&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="316701"&gt;316701&lt;/ulink&gt;]. High-potency agents cause significantly more extrapyramidal side effects and, for many patients, considerable discomfort or subjective dysphoria can result from akathisia or a dystonic reactions [&lt;ulink linkType="reference" linkID="1910"&gt;1910&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="316701"&gt;316701&lt;/ulink&gt;]. Compounds able to affect dopamine circuits in a differential manner, blocking dysregulated systems but sparing normally functioning circuits, are therefore a frontier of research extensively explored by drug developers.&lt;/para&gt;&lt;para&gt;The ergoline derivatives are a family of compounds that, by virtue of their structural relationship to indole- and catecholamines, have a high affinity for recognition sites for serotonin, noradrenaline and dopamine [&lt;ulink linkType="reference" linkID="176198"&gt;176198&lt;/ulink&gt;]. Substitutions at the ergoline ring change the intrinsic activity of the derivative compound at the amine receptors. Recently, several ergoline derivatives that exhibit the properties of dopamine receptor partial agonists have been synthesized [&lt;ulink linkType="reference" linkID="176198"&gt;176198&lt;/ulink&gt;]. Partial agonists can act as synaptic buffers by reducing dopaminergic activity when it is excessive and promoting it when it is reduced [&lt;ulink linkType="reference" linkID="86634"&gt;86634&lt;/ulink&gt;]. This may result in adequate therapeutic efficacy when dopamine imbalance is selective for certain dopaminergic circuits, as in schizophrenia or when dopamine functions fluctuate, as in manic depression or in certain forms of addiction (cocaine dependence, with alternation between 'high' due to cocaine-induced dopamine hyperstimulation and 'low' due to withdrawal). &lt;/para&gt;&lt;para&gt;The Sandoz &lt;ulink linkType="Company" linkID="16019"&gt;Tsukuba Research Institute&lt;/ulink&gt; are developing a novel ergoline derivative, &lt;ulink linkType="Drug" linkID="10003"&gt;SDZ-MAR-327&lt;/ulink&gt;, a partial agonist in phase II clinical trials for schizophrenia [&lt;ulink linkType="reference" linkID="189950"&gt;189950&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="244117"&gt;244117&lt;/ulink&gt;]. This compound has been proven to selectively decrease dopamine metabolism in the cortex while sparing the striatum. This is likely to result in a reduction in adverse side effects [&lt;ulink linkType="reference" linkID="190212"&gt;190212&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Synthesis and SAR&lt;/subtitle&gt;&lt;ulink linkType="Drug" linkID="10003"&gt;SDZ-MAR-327&lt;/ulink&gt; is an 8-alpha-ergoline that exhibits the properties of a dopamine receptor partial agonist. The antagonist properties are suggested to reduce the excessive dopamine transmission associated with the positive symptoms of schizophrenia, while the compound's intrinsic activity prevents motor side effects and treats negative symptoms often attributed to hypodopaminergic states [&lt;ulink linkType="reference" linkID="190212"&gt;190212&lt;/ulink&gt;]. &lt;ulink linkType="Drug" linkID="10003"&gt;SDZ-MAR-327&lt;/ulink&gt; does not elevate prolactin in the rat and produces no catalepsy [&lt;ulink linkType="reference" linkID="176198"&gt;176198&lt;/ulink&gt;]. It markedly increased DOPA in rat brain after inhibition of decarboxylation both in limbic (accumbens) and extrapyramidal (striatum) regions [&lt;ulink linkType="reference" linkID="176197"&gt;176197&lt;/ulink&gt;]. Recently, &lt;ulink linkType="Drug" linkID="10003"&gt;SDZ-MAR-327&lt;/ulink&gt; possesses antagonistic activity at 5-HT2 receptors and agonistic activity at 5-HT1A receptors [&lt;ulink linkType="reference" linkID="175550"&gt;175550&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Pharmacology&lt;/subtitle&gt;The pharmacological profile of &lt;ulink linkType="Drug" linkID="10003"&gt;SDZ-MAR-327&lt;/ulink&gt; is compatible with a partial agonistic activity at the D2 receptor and antagonistic activity at the D1 receptor [&lt;ulink linkType="reference" linkID="175550"&gt;175550&lt;/ulink&gt;]. In the rat substantia nigra (pars compacta), for example, dopamine acting at the D2 receptor inhibits the spontaneous firings and hyperpolarizes the membrane of all neurons [&lt;ulink linkType="reference" linkID="223984"&gt;223984&lt;/ulink&gt;]. &lt;ulink linkType="Drug" linkID="10003"&gt;SDZ-MAR-327&lt;/ulink&gt; (1 to 100 nM) antagonizes the inhibitory effects of DA in a concentration-dependent manner [&lt;ulink linkType="reference" linkID="223984"&gt;223984&lt;/ulink&gt;]. However, at high concentration (1 to 3 microM), &lt;ulink linkType="Drug" linkID="10003"&gt;SDZ-MAR-327&lt;/ulink&gt; induces a partial inhibitory effect on spontaneous firing, suggesting a partial agonistic action on D2 receptors [&lt;ulink linkType="reference" linkID="223984"&gt;223984&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt; &lt;ulink linkType="Drug" linkID="10003"&gt;SDZ-MAR-327&lt;/ulink&gt; also has intrinsic activity at the 5-HT receptors.  &lt;ulink linkType="Drug" linkID="10003"&gt;SDZ-MAR-327&lt;/ulink&gt; inhibits head-twitch responses induced by DOI (a selective 5-HT2 receptor agonist) in the rat [&lt;ulink linkType="reference" linkID="175550"&gt;175550&lt;/ulink&gt;]. &lt;ulink linkType="Drug" linkID="10003"&gt;SDZ-MAR-327&lt;/ulink&gt; (0.3 to 1 mg/kg po) also facilitates 5-HT1A-dependent behavior, such as hind limb abduction and flat body posture, which may be induced by pretreatment with a selective 5-HT1A agonist (8-OH-DPAT) [&lt;ulink linkType="reference" linkID="175550"&gt;175550&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Partial agonist activity at the D2 receptor also has been tested in a cocaine self-administration animal model [&lt;ulink linkType="reference" linkID="277084"&gt;277084&lt;/ulink&gt;]. In a standard lever-pressing operant procedure, rats trained to self-administer cocaine showed a significant increase in the number of lever presses at a dose of 0.5 mg/kg, reflecting a decrease in the reinforcing effects of cocaine. Rats trained to self-administer ethanol also showed a reduction in ethanol intake at a higher dose (1.0 mg/kg). These results suggest the use of &lt;ulink linkType="Drug" linkID="10003"&gt;SDZ-MAR-327&lt;/ulink&gt; in the treatment of substance abuse and dependence.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Metabolism&lt;/subtitle&gt;No data are currently available.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Toxicity&lt;/subtitle&gt;No data are currently available. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Clinical development&lt;/subtitle&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;No data are currently available.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In a study carried out with 18 hospitalized, schizophrenic patients undergoing PET scanning after administration of &lt;ulink linkType="Drug" linkID="10003"&gt;SDZ-MAR-327&lt;/ulink&gt;, haloperidol or placebo, those who had the low &lt;ulink linkType="Drug" linkID="10003"&gt;SDZ-MAR-327&lt;/ulink&gt; dose (150 to 200 mg/day) reported extrapyramidal motor symptoms, whereas those at the higher doses (300 to 400 mg/day) showed no significant motor symptoms [&lt;ulink linkType="reference" linkID="190212"&gt;190212&lt;/ulink&gt;]. These effects are consistent with the metabolic PET findings: the ventral striatum showed increases in metabolism with 150 to 200 mg/day, while no effect was observed following administration of 300 to 400 mg/day [&lt;ulink linkType="reference" linkID="190212"&gt;190212&lt;/ulink&gt;]. It is likely that the striatal effects at low doses are due to D2 blockade in the striatum, while effects at the higher doses may be mediated by D1 blockade, which may balance the effects of D2 blockade [&lt;ulink linkType="reference" linkID="190212"&gt;190212&lt;/ulink&gt;]. Actions at the 5-HT receptors also could contribute to these findings [&lt;ulink linkType="reference" linkID="175550"&gt;175550&lt;/ulink&gt;]. In the single published study in humans, toxic effects were not observed [&lt;ulink linkType="reference" linkID="190212"&gt;190212&lt;/ulink&gt;]. The metabolic effects of &lt;ulink linkType="Drug" linkID="10003"&gt;SDZ-MAR-327&lt;/ulink&gt; in the human brain are dramatic, demonstrating that &lt;ulink linkType="Drug" linkID="10003"&gt;SDZ-MAR-327&lt;/ulink&gt; crosses the brain blood barrier and significantly alters brain metabolism [&lt;ulink linkType="reference" linkID="190212"&gt;190212&lt;/ulink&gt;]. Data on antipsychotic efficacy are not currently available.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Side effects and contraindications&lt;/subtitle&gt;No detailed data are currently available. In the single published study, however, extrapyrimidal motor symptoms were reported in hospitalized schizophrenic patients receiving low dosage (150 to 200 mg/day) &lt;ulink linkType="Drug" linkID="10003"&gt;SDZ-MAR-327&lt;/ulink&gt; [&lt;ulink linkType="reference" linkID="190212"&gt;190212&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Current opinion&lt;/subtitle&gt;Preclinical data show that &lt;ulink linkType="Drug" linkID="10003"&gt;SDZ-MAR-327&lt;/ulink&gt; is likely to be effective as an antidopaminergic compound. Interactions at the 5-HT1A receptors could contribute to the putative low side effect liability of this compound. However, key questions regarding its clinical profile remain unanswered. No data are currently available on the pharmacokinetics and metabolism of the compound. Other ergoline derivatives, such as &lt;ulink linkType="Drug" linkID="2686"&gt;bromerguride&lt;/ulink&gt; (&lt;ulink linkType="Company" linkID="19687"&gt;Schering AG&lt;/ulink&gt;), have a short terminal half-life, without active metabolites [&lt;ulink linkType="reference" linkID="75127"&gt;75127&lt;/ulink&gt;]. A brief half-life may be a limitation in the treatment of schizophrenic patients, who need a 24 h constant therapeutic coverage in the active phase of the disorder. Available data do not allow an estimate of safety and tolerability of the drug in humans. Preliminary results, presented at the Fifth International Congress on Schizophrenia Research (Warm Springs, VA, USA, 8-12 April 1995) seem encouraging [&lt;ulink linkType="reference" linkID="313693"&gt;313693&lt;/ulink&gt;]. However, despite the compound being reported to have a favorable side effect profile, particularly with respect to extrapyramidal symptoms, no detailed data have been published to date and information on its efficacy is limited.&lt;/para&gt;&lt;para&gt;Preliminary results in animals suggest that &lt;ulink linkType="Drug" linkID="10003"&gt;SDZ-MAR-327&lt;/ulink&gt; may be useful in the treatment of substance abuse and dependence [&lt;ulink linkType="reference" linkID="277084"&gt;277084&lt;/ulink&gt;]. This is another area which is worthy of further investigation, since effective drugs for addiction are scarce, with the exception of methadone and naltrexone for heroin addiction and some promising results for alcoholism.&lt;/para&gt;&lt;para&gt;To date there are insufficient controlled studies to foresee the future of this compound in the market. Available data suggest promising results but today's new compounds increasingly face a tough competition and significant results should be sufficiently robust to imply a prospective success.&lt;/para&gt;</ExpertReview><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="299">Schizophrenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1998-06-01T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="24513">Sandoz AB</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1995-10-17T00:00:00.000Z</StatusDate><Source id="189950" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1997-05-01T00:00:00.000Z</StatusDate><Source id="244117" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24572">Sandoz Pharma Ltd</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1992-12-01T00:00:00.000Z</StatusDate><Source id="176198" type="SERIAL"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00011"><Name>5-HT 1a receptor</Name><SwissprotNumbers><Swissprot>P08908</Swissprot><Swissprot>P19327</Swissprot><Swissprot>Q64264</Swissprot><Swissprot>Q6XXX9</Swissprot><Swissprot>Q6XXY0</Swissprot><Swissprot>Q9N296</Swissprot><Swissprot>Q9N297</Swissprot><Swissprot>Q9N298</Swissprot></SwissprotNumbers></Target><Target id="PTGT-00018"><Name>5-HT 2 receptor</Name><SwissprotNumbers></SwissprotNumbers></Target><Target id="PTGT-00632"><Name>Dopamine D1 receptor</Name><SwissprotNumbers><Swissprot>O02664</Swissprot><Swissprot>O77680</Swissprot><Swissprot>P18901</Swissprot><Swissprot>P21728</Swissprot><Swissprot>P35406</Swissprot><Swissprot>P42288</Swissprot><Swissprot>P42289</Swissprot><Swissprot>P50130</Swissprot><Swissprot>Q61616</Swissprot><Swissprot>Q95136</Swissprot></SwissprotNumbers></Target><Target id="PTGT-00633"><Name>Dopamine D2 receptor</Name><SwissprotNumbers><Swissprot>O73810</Swissprot><Swissprot>P14416</Swissprot><Swissprot>P20288</Swissprot><Swissprot>P52702</Swissprot><Swissprot>P60026</Swissprot><Swissprot>P61168</Swissprot><Swissprot>P61169</Swissprot><Swissprot>Q9GJU1</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate></ReasonsForUpdate><StructureSmiles><Smiles>CCC(C)(CC)C(=O)N[C@H]1C[C@@H]2c3cccc4c3c(c([nH]4)C)C[C@H]2NC1</Smiles></StructureSmiles><hasSWOTs>N</hasSWOTs></Drug><Drug id="100033"><DrugName>small molecule photosensitizer (cancer/dermatological disease), Knowa Pharmaceutical</DrugName><DrugSynonyms><Name><Value>small molecule photosensitizer (cancer/dermatological disease), Knowa Pharmaceutical</Value></Name></DrugSynonyms><CompanyOriginator id="1058085">Knowa Pharmaceutical (Shanghai) Co Ltd</CompanyOriginator><CompaniesSecondary><Company id="1058085">Knowa Pharmaceutical (Shanghai) Co Ltd</Company></CompaniesSecondary><CrossReferences><SourceEntity id="1058085" type="Company"><TargetEntity id="5035552041" type="organizationId">Knowa Pharmaceutical (Shanghai) Co Ltd</TargetEntity></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="95" type="ciIndication"><TargetEntity id="10040831" type="MEDDRA"></TargetEntity><TargetEntity id="D012871" type="MeSH"></TargetEntity><TargetEntity id="-57728907" type="omicsDisease"></TargetEntity><TargetEntity id="442" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="651">Cancer</Indication><Indication id="95">Dermatological disease</Indication></IndicationsSecondary><ActionsSecondary><Action id="59620">Unspecified drug target</Action><Action id="799">Photosensitizer</Action><Action id="1545">Anticancer</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>D</Code><Name>DERMATOLOGICALS</Name></Ephmra></EphmraCodes><LastModificationDate>2015-12-08T11:38:08.000Z</LastModificationDate><ChangeDateLast>2015-12-11T00:00:00.000Z</ChangeDateLast><AddedDate>2015-11-26T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;As no development has been reported for some time, this program is assumed to be discontinued.&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="1058085" linkType="Company"&gt;Knowa Pharmaceutical&lt;/ulink&gt; was investigating a small molecule photosensitizer, as a photodynamic diagnostics (PDD) and photodynamic therapy (PDT), for the potential diagnosis and treatment of cancer, and potential treatment of dermatological disease [&lt;ulink linkID="1715949" linkType="Reference"&gt;1715949&lt;/ulink&gt;]. In August 2012, the drug was in preclinical development [&lt;ulink linkID="1715950" linkType="Reference"&gt;1715950&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;By November 2012, the project had received Pudong New District patent application grant [&lt;ulink linkID="1715949" linkType="Reference"&gt;1715949&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="PA7055656" linkType="Patent"&gt;CN-102617378&lt;/ulink&gt;, filed by Knowa Pharmaceutical claims 2-(3'-amino-2'-oxo-propyl)malonate compounds as potential photodynamic drug [&lt;ulink linkID="1715950" linkType="Reference"&gt;1715950&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1058085">Knowa Pharmaceutical (Shanghai) Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="95">Dermatological disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-05-14T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1058085">Knowa Pharmaceutical (Shanghai) Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-05-14T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1058085">Knowa Pharmaceutical (Shanghai) Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="95">Dermatological disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-08-01T00:00:00.000Z</StatusDate><Source id="1715950" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1058085">Knowa Pharmaceutical (Shanghai) Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-08-01T00:00:00.000Z</StatusDate><Source id="1715950" type="OTHER"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=1715950" linkType="reference" linkID="1715950"&gt;1715950&lt;/ulink&gt;]
							</Description></ReasonForUpdate></ReasonsForUpdate><StructureSmiles><Smiles>COC(=O)C(CC(=O)CN)C(=O)OC.OS(=O)(=O)O</Smiles></StructureSmiles><hasSWOTs>N</hasSWOTs></Drug><Drug id="100035"><DrugName>hepatitis delta virus-targeted siRNA therapy (LNP technology, hepatitis delta virus infection), Arbutus Biopharma</DrugName><DrugSynonyms><Name><Value>hepatitis delta virus-targeted siRNA therapy (LNP technology, hepatitis delta virus infection), Arbutus Biopharma</Value></Name></DrugSynonyms><CompanyOriginator id="1032153">Arbutus Biopharma Corp</CompanyOriginator><CompaniesSecondary><Company id="1032153">Arbutus Biopharma Corp</Company></CompaniesSecondary><CrossReferences><SourceEntity id="1032153" type="Company"><TargetEntity id="4295861697" type="organizationId">Arbutus Biopharma Corp (Pre-Merger)</TargetEntity></SourceEntity><SourceEntity id="362" type="ciIndication"><TargetEntity id="10019762" type="MEDDRA"></TargetEntity><TargetEntity id="D019701" type="MeSH"></TargetEntity><TargetEntity id="-472897966" type="omicsDisease"></TargetEntity><TargetEntity id="431" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="991" type="Action"><TargetEntity id="1376" type="Mechanism">BR1 Expression Inhibitors</TargetEntity><TargetEntity id="3051" type="Mechanism">Viral Attachment Inhibitors</TargetEntity><TargetEntity id="3481" type="Mechanism">UL36 Expression Inhibitors</TargetEntity><TargetEntity id="4886" type="Mechanism">Drugs Targeting Hepatitis C Virus (HCV) Proteins</TargetEntity><TargetEntity id="3759" type="Mechanism">L Expression Inhibitors</TargetEntity><TargetEntity id="2436" type="Mechanism">Viral Maturation Inhibitors</TargetEntity><TargetEntity id="4128" type="Mechanism">Flavivirus Guanylyl Transferase (NS5) Inhibitors</TargetEntity><TargetEntity id="5287" type="Mechanism">Drugs Targeting Influenza Virus Proteins</TargetEntity><TargetEntity id="3482" type="Mechanism">UL37 Expression Inhibitors</TargetEntity><TargetEntity id="4476" type="Mechanism">Anti-JC Polyomavirus Capsid Protein</TargetEntity><TargetEntity id="3371" type="Mechanism">Drugs Acting on Influenza Virus Proton Channels</TargetEntity><TargetEntity id="1307" type="Mechanism">Viral Fusion Inhibitors</TargetEntity><TargetEntity id="3575" type="Mechanism">Orthopoxvirus Egress Inhibitors</TargetEntity><TargetEntity id="3235" type="Mechanism">UL29 Expression Inhibitors</TargetEntity><TargetEntity id="5304" type="Mechanism">Drugs Targeting Rabies Virus Proteins</TargetEntity><TargetEntity id="4612" type="Mechanism">Drugs Targeting Human Immunodeficiency Virus 1 (HIV-1) Proteins</TargetEntity><TargetEntity id="4479" type="Mechanism">Drugs Targeting JC Polyomavirus Proteins</TargetEntity><TargetEntity id="2893" type="Mechanism">Human T-Cell Leukemia Virus Type I (HTLV-I) Protease Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="362">Hepatitis D virus infection</Indication></IndicationsSecondary><ActionsSecondary><Action id="991">Antiviral</Action><Action id="26035">siRNA agent</Action><Action id="59620">Unspecified drug target</Action></ActionsSecondary><Technologies><Technology id="103">Oligonucleotide</Technology><Technology id="1668">Nanoparticle formulation</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="349">Lipid</Technology></Technologies><EphmraCodes><Ephmra><Code>J5</Code><Name>ANTIVIRALS FOR SYSTEMIC USE</Name></Ephmra></EphmraCodes><LastModificationDate>2017-04-06T09:11:39.000Z</LastModificationDate><ChangeDateLast>2017-04-06T00:00:00.000Z</ChangeDateLast><AddedDate>2015-11-28T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1032153" linkType="Company"&gt;Arbutus Biopharma&lt;/ulink&gt; is investigating hepatitis delta virus (HDV)-targeted siRNA therapy delivered through the lipid nanoparticle (LNP) platform, for the potential treatment of HDV infection. In November 2015, preclinical data were presented [&lt;ulink linkID="1712994" linkType="Reference"&gt;1712994&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In November 2015, preclinical data were presented at AASLD's Liver Meeting 2015 in San Francisco, CA. In Huh7-D12 cells treated with a single dose of HDAg targeting siRNA-LNP (20 ng/ml, 1.5 nM), there was an immediate and dose-dependent reduction of HDV positive-strand RNA and HDAg protein observed at 24 h and cytoplasmic HDV RNA were more susceptible. Overall, long-lasting duration of activity was exhibited by HDAg mRNA targeting siRNA which rapidly inhibited HDV RNA and proteins [&lt;ulink linkID="1712994" linkType="Reference"&gt;1712994&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt;&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1032153">Arbutus Biopharma Corp</Company><Country id="CA">Canada</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="362">Hepatitis D virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-04-06T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1032153">Arbutus Biopharma Corp</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="362">Hepatitis D virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-11-17T00:00:00.000Z</StatusDate><Source id="1712994" type="OTHER"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><PatentFamilies><PatentFamily id="3445005" number="WO-2016183366" title="Compositions and methods for silencing expression of hepatitis D virus RNA"></PatentFamily><PatentFamily id="3471991" number="WO-2016197132" title="Treating hepatitis B virus infection using CRISPR"></PatentFamily><PatentFamily id="4313611" number="WO-2018232330" title="Therapeutic compositions and methods for treating hepatitis B"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Arbutus Biopharma Corp" id="1032153"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug><Drug id="100041"><DrugName>ADM-23</DrugName><DrugSynonyms><Name><Value>ADM-23</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1004998">Shenyang Pharmaceutical University</CompanyOriginator><CompaniesSecondary><Company id="1004998">Shenyang Pharmaceutical University</Company></CompaniesSecondary><CrossReferences><SourceEntity id="1004998" type="Company"><TargetEntity id="5035524415" type="organizationId">Shenyang Pharmaceutical University</TargetEntity></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity></SourceEntity><SourceEntity id="399" type="Action"><TargetEntity id="884" type="Mechanism">Glucose Lowering Agents</TargetEntity></SourceEntity><SourceEntity id="5537" type="Action"><TargetEntity id="3328" type="Mechanism">Anti-CD26 (Anti-Dipeptidyl Peptidase IV; DPPIV)</TargetEntity><TargetEntity id="415" type="Mechanism">Dipeptidyl Peptidase IV (CD26; DPP-IV; DP-IV) Inhibitors</TargetEntity><TargetEntity id="5399" type="Mechanism">Dipeptidyl peptidase 4 (DPP4) antagonists</TargetEntity></SourceEntity><SourceEntity id="PTGT-00618" type="ciTarget"><TargetEntity id="17367845618033" type="siTarget">Dipeptidyl peptidase 4</TargetEntity><TargetEntity id="8056" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="651">Cancer</Indication></IndicationsSecondary><ActionsPrimary><Action id="5537">Dipeptidyl peptidase IV inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="1545">Anticancer</Action><Action id="38439">DPP IV inhibitor antidiabetic product</Action><Action id="399">Hypoglycemic agent</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>A10B6</Code><Name>DPP-IV inhibitor antidiabetics</Name></Ephmra></EphmraCodes><LastModificationDate>2018-05-30T05:52:48.000Z</LastModificationDate><ChangeDateLast>2018-05-30T00:00:00.000Z</ChangeDateLast><AddedDate>2015-11-28T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;As no development has been reported for some time, this program is assumed to be discontinued.&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="1004998" linkType="Company"&gt;Shenyang Pharmaceutical University&lt;/ulink&gt; was investigating  ADM-23, a DPP-IV inhibitor, for the potential treatment of type 2 diabetes. In November 2015, it was in preclinical studies; at that time, the university was seeking to outlicense this project [&lt;ulink linkID="1708648" linkType="Reference"&gt;1708648&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In November 2015, the university intended to develop ADM-23 as a class 1.1 drug in China [&lt;ulink linkID="1708648" linkType="Reference"&gt;1708648&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1004998">Shenyang Pharmaceutical University</Company><Country id="CN">China</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-05-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1004998">Shenyang Pharmaceutical University</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-11-24T00:00:00.000Z</StatusDate><Source id="1708648" type="CORPORATE"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00618"><Name>Dipeptidyl peptidase IV</Name><SwissprotNumbers><Swissprot>P14740</Swissprot><Swissprot>P22411</Swissprot><Swissprot>P27487</Swissprot><Swissprot>P28843</Swissprot><Swissprot>P81425</Swissprot><Swissprot>Q9N2I7</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=1708648" linkType="reference" linkID="1708648"&gt;1708648&lt;/ulink&gt;]
							</Description></ReasonForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug><Drug id="100043"><DrugName>DHX-11</DrugName><DrugSynonyms><Name><Value>DHX-11</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1004998">Shenyang Pharmaceutical University</CompanyOriginator><CompaniesSecondary><Company id="1004998">Shenyang Pharmaceutical University</Company></CompaniesSecondary><CrossReferences><SourceEntity id="1004998" type="Company"><TargetEntity id="5035524415" type="organizationId">Shenyang Pharmaceutical University</TargetEntity></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="651">Cancer</Indication></IndicationsSecondary><ActionsSecondary><Action id="1545">Anticancer</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2018-05-30T05:50:41.000Z</LastModificationDate><ChangeDateLast>2018-05-30T00:00:00.000Z</ChangeDateLast><AddedDate>2015-11-28T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;As no development has been reported for some time, this program is assumed to be discontinued.&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="1004998" linkType="Company"&gt;Shenyang Pharmaceutical University&lt;/ulink&gt;   was investigating DHX-11, for the potential treatment of cancer. In November 2015, it was in preclinical studies; at that time, the university was seeking to outlicense this project [&lt;ulink linkID="1708648" linkType="Reference"&gt;1708648&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In November 2015,  the university intended to develop DHX-11 as a class 1.1 drug in China  [&lt;ulink linkID="1708648" linkType="Reference"&gt;1708648&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In August 2012, preclinical data in rats were published  [&lt;ulink linkID="1716193" linkType="Reference"&gt;1716193&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;By January 2012, the project was funded by Liaoning government [&lt;ulink linkID="1716191" linkType="Reference"&gt;1716191&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt;&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1004998">Shenyang Pharmaceutical University</Company><Country id="CN">China</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-05-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1004998">Shenyang Pharmaceutical University</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-01-31T00:00:00.000Z</StatusDate><Source id="1716191" type="OTHER"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>3 references added [&lt;ulink url="utility.reference?i_reference_id=1716193" linkType="reference" linkID="1716193"&gt;1716193&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=1708648" linkType="reference" linkID="1708648"&gt;1708648&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=1716191" linkType="reference" linkID="1716191"&gt;1716191&lt;/ulink&gt;]
							</Description></ReasonForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug><Drug id="100045"><DrugName>S-52</DrugName><DrugSynonyms><Name><Value>S-52</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>S-1 derivative (Alzheimers disease), Shanghai Institute of Materia Medica</Value></Name></DrugSynonyms><CompanyOriginator id="25314">Shanghai Institute of Materia Medica of the Chinese Academy of Sciences</CompanyOriginator><CompaniesSecondary><Company id="25314">Shanghai Institute of Materia Medica of the Chinese Academy of Sciences</Company></CompaniesSecondary><CrossReferences><SourceEntity id="25314" type="Company"><TargetEntity id="5035554591" type="organizationId">Shanghai Institute of Materia Medica Chinese Academy of Sciences</TargetEntity></SourceEntity><SourceEntity id="14" type="ciIndication"><TargetEntity id="G30" type="ICD10"></TargetEntity><TargetEntity id="331.0" type="ICD9"></TargetEntity><TargetEntity id="10012271" type="MEDDRA"></TargetEntity><TargetEntity id="D000544" type="MeSH"></TargetEntity><TargetEntity id="-1268969445" type="omicsDisease"></TargetEntity><TargetEntity id="101" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="421" type="Action"><TargetEntity id="862" type="Mechanism">Cholinergics</TargetEntity><TargetEntity id="19" type="Mechanism">Acetylcholine Precursors</TargetEntity></SourceEntity><SourceEntity id="263" type="Action"><TargetEntity id="3232" type="Mechanism">Nerve Growth Factor (NGF) Enhancers</TargetEntity></SourceEntity><SourceEntity id="PTGT-01422" type="ciTarget"><TargetEntity id="9364897148043" type="siTarget">Tumor necrosis factor receptor superfamily member 16</TargetEntity><TargetEntity id="526" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="14">Alzheimers disease</Indication></IndicationsSecondary><ActionsPrimary><Action id="263">NGF receptor agonist</Action><Action id="421">Acetylcholine receptor agonist</Action></ActionsPrimary><ActionsSecondary><Action id="1615">Neuroprotectant</Action><Action id="284">Nootropic agent</Action></ActionsSecondary><Technologies><Technology id="1647">Natural product</Technology></Technologies><EphmraCodes><Ephmra><Code>N6D</Code><Name>NOOTROPICS</Name></Ephmra></EphmraCodes><LastModificationDate>2015-11-26T08:24:20.000Z</LastModificationDate><ChangeDateLast>2015-11-28T00:00:00.000Z</ChangeDateLast><AddedDate>2015-11-28T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="25314" linkType="Company"&gt;Shanghai Institute of Materia Medica&lt;/ulink&gt; was investigating S-52, a derivative  of S-1, a alkaloid derived from a traditional Chinese herbal medicine, for the potential treatment of Alzheimer's disease. In October 2012, the drug was in preclinical development [&lt;ulink linkID="1716204" linkType="Reference"&gt;1716204&lt;/ulink&gt;]. In April 2011, the institute was seeking to outlicense this project [&lt;ulink linkID="1716203" linkType="Reference"&gt;1716203&lt;/ulink&gt;]. However, no development has been reported since October 2012.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In April 2011, the institute intended to develop S-52 as a class 1 drug in China [&lt;ulink linkID="1716203" linkType="Reference"&gt;1716203&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In October 2012, preclinical data were published. S-52 protected against beta-amyloid induced neuronal injury by attenuating mitochondrial dysfunction [&lt;ulink linkID="1716204" linkType="Reference"&gt;1716204&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2011, data from preclinical studies on rats and mice were published. Intraperitoneal injection of S-52 in rats significantly improved their memory abilities. Oral administration of S-52 to mice significantly reversed the scopolamine-associated memory disorders. S-52 not only had nootropic effects, it also raised acetylcholine levels in the brain and  increased nerve growth factor production [&lt;ulink linkID="1716203" linkType="Reference"&gt;1716203&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt;&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="25314">Shanghai Institute of Materia Medica of the Chinese Academy of Sciences</Company><Country id="CN">China</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-04-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="25314">Shanghai Institute of Materia Medica of the Chinese Academy of Sciences</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-07-21T00:00:00.000Z</StatusDate><Source id="1716206" type="PR"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00042"><Name>Acetylcholine receptor</Name><SwissprotNumbers></SwissprotNumbers></Target><Target id="PTGT-01422"><Name>NGF receptor</Name><SwissprotNumbers><Swissprot>P07174</Swissprot><Swissprot>P08138</Swissprot><Swissprot>P18519</Swissprot><Swissprot>Q9Z0W1</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>3 references added [&lt;ulink url="utility.reference?i_reference_id=1716204" linkType="reference" linkID="1716204"&gt;1716204&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=1716203" linkType="reference" linkID="1716203"&gt;1716203&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=1716206" linkType="reference" linkID="1716206"&gt;1716206&lt;/ulink&gt;]
							</Description></ReasonForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordsOutput>